secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056286
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q1 net loss $107M; cash $953M; Phase 3 enrollment ahead; FDA alignment on ATTRv-PN trial
--------------------------------------------------------------------------------

- Net loss of $107.4M for Q1 2024; collaboration revenue $28.9M (up from $12.6M YoY) on $21M non-cash adjustment.
- Cash and marketable securities $953.4M as of Mar 31, 2024; expected to fund operations into late 2026.
- Phase 3 MAGNITUDE trial for ATTR-CM enrolling ahead of projections; over 30 patients dosed, 40+ in screening.
- FDA alignment on pivotal Phase 3 design for NTLA-2001 in ATTRv-PN; study of ~50 patients to initiate by year-end.
- On track to initiate NTLA-2002 Phase 3 for HAE in H2 2024; Phase 1 long-term data at EAACI June 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/0000950170-24-056286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/ntla-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer